Who
David O. Watson
General Counsel
Company insider
Files Form 4 as: General Counsel, Apellis Pharmaceuticals.
In numbers
- Trades disclosed
- 173
- Buys
- 0
- Sells
- 32
- Bought
- $0
- Sold
- $7.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Feb 2018
- Last trade
- 14 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —144,517 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —55,986 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —55,986 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —32,072 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —55,986 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —11,874 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —6,001 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code D | —7,363 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,974 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —10,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —38,250 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —37,708 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —34,533 | filing |
| 14 May 2026filed 14 May 2026 | Apellis PharmaceuticalsBiotechnology | SEC FORM 4 Code U | —50,136 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —82,500 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —14,000 | filing |
| 14 May 2026filed 14 May 2026 | Apellis Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —50,974 | filing |
News
No headline names them, or the companies they trade most, lately.